The relevant disclosure is attached
Awaiting price reaction for this filing.
Fortis Healthcare's Q4 FY25 earnings call discussed consolidated revenue of INR 2,007 crores (+12.4% YoY) and full-year FY25 revenue of INR 7,783 crores (+12.9% YoY). The hospital business drove growth with FY25 revenue of INR 6,528 crores (+14.8%) and EBITDA margins improving from 18.6% to 20.5%, contributing 84% to consolidated revenue and EBITDA. Diagnostic arm Agilus saw EBITDA margins expand to 22% (ex-one-offs) and the company raised its stake to 89.2% by buying 31.52% from PE investors. Key developments include acquiring the 'Fortis' brand for INR 200 crores, signing an INR 462 crore deal for Shrimann Superspecialty Hospital in Jalandhar (228 beds, expandable to 450+), and plans to add ~2,000 beds over 2-3 years. Hospital occupancy improved to 69% (from 65%) and ARPOB grew 9% to INR 2.42 crores. The Board recommended a INR 1 per share dividend for the third consecutive year.
Positive signals for shareholders — management has guided for 14-15% revenue growth and ~200 bps margin expansion in FY26, supported by brownfield capacity additions at existing high-occupancy facilities and the elimination of brand royalty costs. Net debt/EBITDA rose to 0.93x from 0.17x due to NCD issuance and Agilus stake purchase, but no incremental debt is planned for brownfield expansion.